<DOC>
	<DOC>NCT01649427</DOC>
	<brief_summary>The purpose of this study is to investigate if Tacrolimus Hexal速 has similar pharmacokinetic properties compared to Prograf速 in de novo renal transplant patients and whether the comparable exposure results in similar renal function.</brief_summary>
	<brief_title>Comparison of a Tacrolimus Hexal速 Based Regimen Versus a Prograf速 Based Regimen in de Novo Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion: primary or sec. kidney transplanted patiens, written consent, cold ischemia &lt; 24 h Exclusion: multi organ, immunological risc pts., PRA &gt;20%, Antibodys against HLAtype of donor organ, hypersensitivity against Tacro or MMF, Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pharmacokinetics Study</keyword>
	<keyword>Tacroliums</keyword>
	<keyword>GFR</keyword>
	<keyword>kdney</keyword>
</DOC>